Manulife Financial Corporation vs Summit Therapeutics Inc — how do they compare? Manulife Financial Corporation trades at $43.99 (market cap $72.68B), while Summit Therapeutics Inc trades at $15.28 (market cap $12.06B). The key difference: Manulife Financial Corporation is far larger — about 6× Summit Therapeutics Inc's market cap, and Manulife Financial Corporation pays a 3.1% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MFC | SMMT | |
|---|---|---|
Market Cap | $72.68B | $12.06B |
Sector | Financials | Health |
52-Week High | $44.77 | $26.98 |
52-Week Low | $30.06 | $12.55 |
Enterprise Value | $67.84B | $11.39B |
Dividend Yield | 3.1% | — |
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $44.15, down 0.38% on the day, with a bullish technical signal from moving averages and neutral oscillators. Revenue grew to $53.01B in 2025, with net income of $5.78B, and the company has a strong analyst consensus of 57% buy ratings. Recent Q2 2026 earnings beat expectations, driven by Asia growth and insurance sales, while dividends of $0.49 per share were declared for H1 and H2 2026.
MFC's outlook is positive due to earnings momentum and strategic AI partnerships, but risks include premium valuation and segment volatility. The stock offers steady dividends and growth potential, though investors should monitor execution in wealth management and macroeconomic impacts on insurance demand.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Trailing returns across standard periods
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →